Capitala Group, a leading private markets investment firm providing capital solutions to lower middle-market companies, has announced the sale of LifeSync Corporation, a developer, manufacturer, and marketer of disposable and reusable patient monitoring devices and connections sold to hospitals and other high acuity settings, to Amphenol Corporation (“Amphenol”). Capitala was invested in LifeSync alongside HealthEdge Investment Partners and has now fully exited its equity position as part of the transaction.

“We are pleased to have supported LifeSync’s growth and development over the years, and we are confident that they will continue to drive innovation in this space,” said Adam Richeson, Managing Director of Capitala Group.

Read full press release here.